NVST Stock Analysis: Envista Holdings | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 3.749m USD | 12M Return: 13.9% | US29415F1049 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 70.1M
EPS Trend: -17.6%
Qual. Beats: 1
Rev. Trend: 71.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Envista Holdings Corporation (NYSE: NVST) is a Brea, California-based dental products company that develops, manufactures, markets, and sells dental products across the United States, China, and international markets. The company operates through two reportable segments: Specialty Products & Technologies, which covers dental implants, guided surgery, biomaterials, prosthetics, and orthodontic products (including clear aligners and digital treatment software); and Equipment & Consumables, which provides dental imaging systems, endodontic systems, restorative materials, impression materials, bonding agents, and infection prevention products.
The company markets its products under a broad portfolio of established brands, including Nobel Biocare, Ormco, Spark, and Damon in the specialty segment, and Dexis, Kerr, Metrex, Sybron Endo, and CaviWipes in the equipment and consumables segment. Customers include oral surgeons, prosthodontists, periodontists, general dentists, dental offices, clinics, and hospitals. Envista was incorporated in 2018 and completed its IPO in September 2019.
As a Health Care Equipment company (per GICS classification), Envista operates a multi-brand, business-to-business distribution model that sells consumables, equipment, and specialty solutions to dental professionals worldwide, with its product mix spanning consumable supplies, capital equipment, and digital dental software platforms.
- China dental implant and equipment demand recovery drives segment revenue
- Spark clear aligners growth pressures Align Technology market share
- Brea-headquartered Envista expands Specialty Products margin through premium implant brands
- FX headwinds and pricing competition compress Equipment & Consumables margins
| Net Income: 95.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.40 > 1.0 |
| NWC/Revenue: 40.28% < 20% (prev 44.69%; Δ -4.41% < -1%) |
| CFO/TA 0.05 > 3% & CFO 299.3m > Net Income 95.0m |
| Net Debt (614.1m) to EBITDA (406.0m): 1.51 < 3 |
| Current Ratio: 2.43 > 1.5 & < 3 |
| Outstanding Shares: last quarter (164.1m) vs 12m ago -3.41% < -2% |
| Gross Margin: 55.50% > 18% (prev 54.72%; Δ 0.78% > 0.5%) |
| Asset Turnover: 50.73% > 50% (prev 45.07%; Δ 5.66% > 0%) |
| Interest Coverage Ratio: 7.19 > 6 (EBIT TTM 254.7m / Interest Expense TTM 35.4m) |
| A: 0.21 (Total Current Assets 1.96b - Total Current Liabilities 807.3m) / Total Assets 5.60b |
| B: -0.06 (Retained Earnings -348.0m / Total Assets 5.60b) |
| C: 0.05 (EBIT TTM 254.7m / Avg Total Assets 5.63b) |
| D: 1.22 (Book Value of Equity 3.08b / Total Liabilities 2.52b) |
| Altman-Z'' = 2.73 = A |
| DSRI: 0.92 (Receivables 436.9m/422.8m, Revenue 2.86b/2.55b) |
| GMI: 0.99 (GM 54.72% / 55.50%) |
| AQI: 0.98 (AQ_t 0.57 / AQ_t-1 0.58) |
| SGI: 1.12 (Revenue 2.86b / 2.55b) |
| TATA: -0.04 (NI 95.0m - CFO 299.3m) / TA 5.60b) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of October 12, 2026, the stock is trading at USD 23.00 with a total of 2,357,665 shares traded. Over the past week, the price has changed by -1.96%, over one month by -12.94%, over three months by -10.71% and over the past year by +13.92%.
Current recommended Stop Loss: 22.00 (which is 4.3% or 1.4 ATR below the current price).
Envista Holdings has received a consensus analysts rating of 3.93. Therefore, it is recommended to buy NVST.
- StrongBuy: 6
- Buy: 2
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 30 | 30.4% |
P/E Trailing = 40.2414
P/E Forward = 16.8067
P/S = 1.3124
P/B = 1.2437
Revenue TTM = 2.86b USD
EBIT TTM = 254.7m USD
EBITDA TTM = 406.0m USD
Long Term Debt = 1.44b USD (from longTermDebt, last quarter)
Short Term Debt = 38.5m USD (from shortTermDebt, last quarter)
Debt = 1.74b USD (from shortLongTermDebtTotal, last quarter) + Leases 151.7m
Net Debt = 614.1m USD (calculated: Debt 1.74b - CCE 1.13b)
Enterprise Value = 4.36b USD (3.75b + Debt 1.74b - CCE 1.13b)
Interest Coverage Ratio = 7.19 (Ebit TTM 254.7m / Interest Expense TTM 35.4m)
EV/FCF = 18.78x (Enterprise Value 4.36b / FCF TTM 232.3m)
FCF Yield = 5.32% (FCF TTM 232.3m / Enterprise Value 4.36b)
FCF Margin = 8.13% (FCF TTM 232.3m / Revenue TTM 2.86b)
Net Margin = 3.33% (Net Income TTM 95.0m / Revenue TTM 2.86b)
Gross Margin = 55.50% ((Revenue TTM 2.86b - Cost of Revenue TTM 1.27b) / Revenue TTM)
Gross Margin QoQ = 55.72% (prev 55.29%)
Tobins Q-Ratio = 0.78 (Enterprise Value 4.36b / Total Assets 5.60b)
Interest Expense / Debt = 2.03% (Interest Expense 35.4m / Debt 1.74b)
Taxrate = 27.82% (20.7m / 74.4m)
NOPAT = 183.8m (EBIT 254.7m * (1 - 27.82%))
Current Ratio = 2.43 (Total Current Assets 1.96b / Total Current Liabilities 807.3m)
Debt / Equity = 0.57 (Debt 1.74b / totalStockholderEquity, last quarter 3.08b)
Debt / EBITDA = 1.51 (Net Debt 614.1m / EBITDA 406.0m)
Debt / FCF = 2.64 (Net Debt 614.1m / FCF TTM 232.3m)
Total Stockholder Equity = 3.09b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.69% (Net Income 95.0m / Total Assets 5.60b)
RoE = 3.08% (Net Income TTM 95.0m / Total Stockholder Equity 3.09b)
RoCE = 5.63% (EBIT 254.7m / Capital Employed (Equity 3.09b + L.T.Debt 1.44b))
RoIC = 3.92% (NOPAT 183.8m / Invested Capital 4.69b)
WACC = 7.72% (E(3.75b)/V(5.49b) * Re(10.62%) + D(1.74b)/V(5.49b) * Rd(2.03%) * (1-Tc(0.28)))
Discount Rate = 10.62% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -89.57 | Cagr: -2.42%
[DCF] Terminal Value 73.97% ; FCFF base≈242.5m ; Y1≈223.2m ; Y5≈198.6m
[DCF] Fair Price = 15.79 (EV 3.15b - Net Debt 614.1m = Equity 2.54b / Shares 160.6m; r=8.35% [WACC [floored]]; 5y FCF grow -9.93% → 2.50% )
EPS Correlation: -17.56 | EPS CAGR: -5.85% | SUE: 1.07 | # QB: 1
Revenue Correlation: 71.86 | Revenue CAGR: 3.65% | SUE: 0.54 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.36 | Chg30d=-1.00% | Revisions=-50% | Analysts=14
EPS current Year (2026-12-31): EPS=1.53 | Chg30d=-0.08% | Revisions=-17% | GrowthEPS=+28.7% | GrowthRev=+5.9%
EPS next Year (2027-12-31): EPS=1.67 | Chg30d=-0.11% | Revisions=-12% | GrowthEPS=+8.8% | GrowthRev=+3.6%
[Analyst] Revisions Ratio: -36% (up=3, down=8)